An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer

This indirect analysis suggests sunitinib and pazopanib have distinct toxicity profiles which may help guide patient's choice. Further comparative data from randomised trials are awaited.